Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease?
about
Tau-targeted treatment strategies in Alzheimer's diseaseQuantitative in vivo measurement of early axonal transport deficits in a triple transgenic mouse model of Alzheimer's disease using manganese-enhanced MRIAnimal models for Alzheimer's disease and frontotemporal dementia: a perspectiveResveratrol Attenuates Formaldehyde Induced Hyperphosphorylation of Tau Protein and Cytotoxicity in N2a CellsNeurobiology of Alzheimer's Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive DimensionsDifferential effect of three-repeat and four-repeat tau on mitochondrial axonal transport.Neuroproteomics as a promising tool in Parkinson's disease research.Dipeptidyl peptidase 10 (DPP10(789)): a voltage gated potassium channel associated protein is abnormally expressed in Alzheimer's and other neurodegenerative diseases.Convergence of amyloid-beta and tau pathologies on mitochondria in vivo.Early oligodendrocyte/myelin pathology in Alzheimer's disease mice constitutes a novel therapeutic target.Familial amyloid precursor protein mutants cause caspase-6-dependent but amyloid β-peptide-independent neuronal degeneration in primary human neuron cultures.Targeting axonal protein synthesis in neuroregeneration and degeneration.Aging, Alzheimer's, and APOE genotype influence the expression and neuronal distribution patterns of microtubule motor protein dynactin-P50Mitochondrial dysfunction - the beginning of the end in Alzheimer's disease? Separate and synergistic modes of tau and amyloid-β toxicityENU mutagenesis screen to establish motor phenotypes in wild-type mice and modifiers of a pre-existing motor phenotype in tau mutant mice.The protein phosphatase PP2A/Bα binds to the microtubule-associated proteins Tau and MAP2 at a motif also recognized by the kinase Fyn: implications for tauopathies.The Role of Insulin and Insulin-Like Growth Factor-1/FoxO-Mediated Transcription for the Pathogenesis of Obesity-Associated Dementia.No Overt Deficits in Aged Tau-Deficient C57Bl/6.Mapttm1(EGFP)Kit GFP Knockin MiceUsp14 deficiency increases tau phosphorylation without altering tau degradation or causing tau-dependent deficits.The Tau/A152T mutation, a risk factor for frontotemporal-spectrum disorders, leads to NR2B receptor-mediated excitotoxicity.Structural principles of tau and the paired helical filaments of Alzheimer's disease.A decade of tau transgenic animal models and beyond.Glutamate metabolism is impaired in transgenic mice with tau hyperphosphorylationLooking for novel ways to treat the hallmarks of Alzheimer's disease.Tau aggregation in Alzheimer's disease: what role for phosphorylation?An update on the toxicity of Abeta in Alzheimer's disease.Phosphorylated Tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1) in Alzheimer disease.Brief update on different roles of tau in neurodegeneration.Recent rodent models for Alzheimer's disease: clinical implications and basic research.Axonal degeneration in Alzheimer's disease: when signaling abnormalities meet the axonal transport system.Regulatable transgenic mouse models of Alzheimer disease: onset, reversibility and spreading of Tau pathology.Recent Progress in Alzheimer's Disease Research, Part 1: Pathology.Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid.Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human Tau.SRPK2 phosphorylates tau and mediates the cognitive defects in Alzheimer's disease.Analysis of isoform-specific tau aggregates suggests a common toxic mechanism involving similar pathological conformations and axonal transport inhibition.Axonal Degeneration in Tauopathies: Disease Relevance and Underlying Mechanisms.Prion protein inhibits fast axonal transport through a mechanism involving casein kinase 2.Dysregulation of Rab5-Mediated Endocytic Pathways in Alzheimer's Disease.Progressive Pathological Changes in Neurochemical Profile of the Hippocampus and Early Changes in the Olfactory Bulbs of Tau Transgenic Mice (rTg4510).
P2860
Q27023429-A6DF40A6-00CB-4ACB-B03D-135B67983C04Q28744424-8311441C-7498-435A-AB06-0EC41E69E7F2Q28749702-493D7837-A104-42A4-AE6B-50B865ACBDE0Q30363322-EE8FCEB5-57F1-400E-9AF9-9DAE5F493522Q30998279-0E346460-1EFD-49F9-A198-1E9061BB2F02Q33700664-2898083B-1252-48F3-9D58-8F4EE451B7EBQ33821316-49E3EA89-6BD8-4446-B5A2-C8B0710214D4Q33855018-55E12255-5497-4524-A526-101F3ABD1A9EQ33876147-547702B8-CDBA-431D-858A-5A5BE2FEB115Q34086988-89CAA2DA-17D2-48CD-8152-5DB5DA96FCC7Q34545392-525E44FD-0600-45A1-91F4-4FE0A7CE9B0BQ35064944-2C48DD1F-C3A9-454F-B8AB-E46390A29737Q35216177-DBB98B75-96D7-44BD-AE65-833F52253781Q35579318-C2AD7664-EC91-4D4C-8724-C5A078110BC4Q35636403-FA37D07C-5728-41FA-B0E5-C0BA2469CAB9Q35922428-E70E5C6D-BF55-492A-9AF0-0BA5541A4249Q35986310-11C126B7-2098-4FDA-95B7-433DDFBA57E0Q36162472-F5A4DFC9-CD20-4A09-93EB-DB279AB86F9EQ36354014-5F76A384-D21E-42ED-BDCC-9AA5E7FF3A91Q36759557-567C4746-E08B-4930-98C0-987E860727D1Q36817219-01840E9D-BB3F-42A5-ABFD-8081CB946CF6Q36817223-386F4674-C944-451A-A943-27B4270457EDQ36840001-0144712C-03F3-4F02-9819-2562A24F9E27Q36904846-E8AA7FF7-A592-43EF-9F4C-96F8A418B694Q37079414-A84D6FD7-AA6F-47A2-8ACE-9F668542EBACQ37106932-0372EA55-7215-4FE7-BFAD-6897C810D365Q37344062-BC0F08B4-EC0A-47DD-852A-A1E00424EE91Q37893588-C6C9AB73-BA7A-42F2-A05D-57C55D468E36Q37956513-AA530A3F-9406-466F-9A91-C2149EB30E4CQ38020618-CD232DA4-D087-43F2-BC7D-157037C66778Q38091721-01C4AF9E-6A78-4CBA-BAF8-6395A63D2A08Q39145449-6267C31D-F659-42D9-A805-C0F7A5C77A45Q41907099-15FE3E47-89BE-461A-8DB7-984E46582244Q42280027-7DFB3F07-B047-42C1-997C-EC8CB736E8C2Q42401404-FBB73A10-DBA4-40FF-A8C5-A6335645E8B8Q42714396-7854C891-6203-41C9-9490-02BA7DB4009BQ46985283-8A02194E-720E-4045-A6E3-77C5EF4D6C88Q47271332-7E95ADF7-C386-4D06-B3F1-3E392D6FB65AQ47875216-F36DA0B5-D9C4-4489-9946-4492113EF5E5Q48123303-90A38FE0-EE0C-4C49-88D2-473308598865
P2860
Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease?
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Do axonal defects in tau and a ...... opathy in Alzheimer's disease?
@ast
Do axonal defects in tau and a ...... opathy in Alzheimer's disease?
@en
type
label
Do axonal defects in tau and a ...... opathy in Alzheimer's disease?
@ast
Do axonal defects in tau and a ...... opathy in Alzheimer's disease?
@en
prefLabel
Do axonal defects in tau and a ...... opathy in Alzheimer's disease?
@ast
Do axonal defects in tau and a ...... opathy in Alzheimer's disease?
@en
P2860
P1476
Do axonal defects in tau and a ...... opathy in Alzheimer's disease?
@en
P2093
Stefan Kins
P2860
P304
P356
10.1111/J.1471-4159.2006.03955.X
P407
P577
2006-06-19T00:00:00Z